682 related articles for article (PubMed ID: 15583670)
21. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
22. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
23. Canada to change patent law to allow export of cheap drugs.
Kondro W
Lancet; 2003 Oct; 362(9392):1290. PubMed ID: 14577437
[No Abstract] [Full Text] [Related]
24. Market exclusivity for biologics.
Wheadon DE
N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
[No Abstract] [Full Text] [Related]
25. Maximizing exclusivity for drug products.
French H
Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
[No Abstract] [Full Text] [Related]
26. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
27. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
28. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
Effingham AM
Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
[No Abstract] [Full Text] [Related]
29. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
Lipschitz Y; Tamir O; Shemer J
Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
[TBL] [Abstract][Full Text] [Related]
30. Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS
N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
[No Abstract] [Full Text] [Related]
31. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
32. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
33. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
34. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
35. Data and market exclusivity for pharmaceuticals in the European Community.
Kingham RF; Castle GH
Food Drug Law J; 2000; 55(2):209-23. PubMed ID: 12269365
[No Abstract] [Full Text] [Related]
36. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
37. US trade rules seek to balance health and patent protection.
Wadman M; Cherry M
Nature; 1999 Dec; 402(6762):567-8. PubMed ID: 10604448
[No Abstract] [Full Text] [Related]
38. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.
Kim J; Ross JS; Kapczynski A
JAMA; 2018 Jan; 319(1):21-22. PubMed ID: 29117365
[No Abstract] [Full Text] [Related]
39. Overview of the Hatch-Waxman Act and its impact on the drug development process.
Mossinghoff GJ
Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
[No Abstract] [Full Text] [Related]
40. Intellectual property. Drug patents at the Supreme Court.
Hemphill CS; Sampat B
Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
